Researchmoz added Most up-to-date research on "Uveitis Therapeutics in Asia-Pacific Markets to 2023 - Increasing Prevalence, Continued Uptake of Biologics and Novel Pipeline Drugs to Drive the Market" to its huge collection of research reports.
Uveitis refers to inflammation of the uvea, the middle vascular coat of the eye, comprising the iris, ciliary body, and choroid. It may also involve other adjacent tissues of the eye. Uveitis occurs at any age, but it most commonly affects individuals between 20 and 59 years of age. However, this trend is changing; the percentage of elderly uveitis patients has been increasing in recent years. Uveitis represents a major cause of ocular morbidity worldwide and often results in complications such as cataracts, glaucoma, ocular hypertension, macular issues, and retinal detachment.
To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1641312
It is a leading cause of blindness in both developed and developing countries and is the fifth most common cause of vision loss in the developed world. The uveitis market is characterized by a small selection of marketed drug options, consisting of corticosteroid therapies, immunosuppressive therapies and biologics. Historically, corticosteroid therapies have made up the bulk of the uveitis market.
Currently only one targeted therapy is available in the Asia-Pacific uveitis market, which is AbbVie’s Humira (adalimumab). The late-stage uveitis pipeline is composed of Santen’s Opsiria and Clearside Biomedical’s CLS-TA, which are expected to be highly lucrative and address some of the unmet needs.
These new drugs will expand the options available to treat uveitis patients and contribute to overall market growth by offering novel treatment mechanisms, including new drug delivery routes and novel, non-corticosteroid drug molecules.
Scope
The Asia-Pacific uveitis market will be valued at $405.5m in 2023, growing from $179m in 2016, at a compound annual growth rate of 12.4%.
What are the key factors driving the Asia-Pacific uveitis treatment market?
How will targeted therapies such as Humira contribute to growth?
Do branded therapies show continuous growth, and are they facing competition from generics?
How will branded therapies be affected by upcoming pipeline therapies?
Corticosteroid therapies dominate the uveitis market, but unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs?
What are the common targets and mechanisms of action of pipeline therapies?
What are the commercial prospects for the most promising late-stage products?
Various drivers and barriers will influence the market over the forecast period.
What are the barriers that will limit the uptake of premium-priced therapies in the assessed countries?
Which factors are most likely to drive the market in these countries?
What licensing and co-development deals have occurred within this therapy area since 2006?
Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/enquiry.php?type=E&repid=1641312
Reasons to buy
Understand the current clinical and commercial landscape through a comprehensive analysis of disease symptoms, diagnostic methods, etiology, pathophysiology, epidemiology, prognosis and treatment.
Visualize the composition of the uveitis market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
Analyze the uveitis pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
Predict uveitis market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
Identify commercial opportunities in the uveitis deals landscape by analyzing trends in licensing and co-development deals.
Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Disease Introduction 9
2.2 Epidemiology 10
2.3 Symptoms 11
2.4 Etiology and Pathophysiology 11
2.4.1 Autoimmune uveitis 12
2.4.2 Non-autoimmune uveitis 12
2.5 Diagnosis 14
2.6 Prognosis 15
2.7 Treatment Options 16
2.7.1 Corticosteroids 17
2.7.2 Immunosuppressive Agents 18
2.7.3 Biologics 18
2.7.4 Adjuvant Therapy 19
3 Marketed Products 20
3.1 Overview 20
3.1.1 Humira (adalimumab) - AbbVie 21
3.1.2 Retisert (fluocinolone acetonide) - Bausch & Lomb 22
3.1.3 Ozurdex (dexamethasone) - Allergan 23
3.1.4 Neoral (Cyclosporine) - Novartis 25
3.1.5 Mycept (Mycophenolate mofetil) - Panacea Biotec 26
3.1.6 Medrol (Methylprednisolone) - Pfizer 27
3.1.7 Betamethasone - Merck & Co. 28
3.1.8 Pred Forte (Prednisolone) - Allergan 28
3.2 Comparative Efficacy and Safety of Marketed Products 29
4 Pipeline Analysis 32
4.1 Overview 32
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 33
4.3 Pipeline by Molecular Target 34
4.4 Promising Pipeline Candidates 36
4.4.1 DE-109/ Opsiria (Sirolimus) - Santen 36
4.4.2 CLS-TA (triamcinolone acetonide) - Clearside BioMedical 37
4.5 Heatmap for Pipeline Products 38
4.6 Product Competitiveness Framework 40
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1641312
5 Clinical Trial Analysis 42
5.1 Failure Rate 42
5.1.1 Overall Failure Rate 42
5.1.2 Failure Rate by Phase and Molecule Type 43
5.1.3 Failure Rate by Phase and Molecular Target 44
5.2 Clinical Trial Size 45
5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development 45
5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development 46
5.2.3 Patient Enrollment per Trial by Molecule Type and Stage of Development 47
5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development 48
5.3 Clinical Trial Duration 49
5.3.1 Trial Duration by Molecule Type and Stage of Development 49
5.3.2 Trial Duration by Molecular Target and Stage of Development 50
5.4 Summary of Clinical Trial Metrics 51
Continue...
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on @ https://marketsizeinfo.blogspot.in/
Uveitis refers to inflammation of the uvea, the middle vascular coat of the eye, comprising the iris, ciliary body, and choroid. It may also involve other adjacent tissues of the eye. Uveitis occurs at any age, but it most commonly affects individuals between 20 and 59 years of age. However, this trend is changing; the percentage of elderly uveitis patients has been increasing in recent years. Uveitis represents a major cause of ocular morbidity worldwide and often results in complications such as cataracts, glaucoma, ocular hypertension, macular issues, and retinal detachment.
To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1641312
It is a leading cause of blindness in both developed and developing countries and is the fifth most common cause of vision loss in the developed world. The uveitis market is characterized by a small selection of marketed drug options, consisting of corticosteroid therapies, immunosuppressive therapies and biologics. Historically, corticosteroid therapies have made up the bulk of the uveitis market.
Currently only one targeted therapy is available in the Asia-Pacific uveitis market, which is AbbVie’s Humira (adalimumab). The late-stage uveitis pipeline is composed of Santen’s Opsiria and Clearside Biomedical’s CLS-TA, which are expected to be highly lucrative and address some of the unmet needs.
These new drugs will expand the options available to treat uveitis patients and contribute to overall market growth by offering novel treatment mechanisms, including new drug delivery routes and novel, non-corticosteroid drug molecules.
Scope
The Asia-Pacific uveitis market will be valued at $405.5m in 2023, growing from $179m in 2016, at a compound annual growth rate of 12.4%.
What are the key factors driving the Asia-Pacific uveitis treatment market?
How will targeted therapies such as Humira contribute to growth?
Do branded therapies show continuous growth, and are they facing competition from generics?
How will branded therapies be affected by upcoming pipeline therapies?
Corticosteroid therapies dominate the uveitis market, but unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs?
What are the common targets and mechanisms of action of pipeline therapies?
What are the commercial prospects for the most promising late-stage products?
Various drivers and barriers will influence the market over the forecast period.
What are the barriers that will limit the uptake of premium-priced therapies in the assessed countries?
Which factors are most likely to drive the market in these countries?
What licensing and co-development deals have occurred within this therapy area since 2006?
Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/enquiry.php?type=E&repid=1641312
Reasons to buy
Understand the current clinical and commercial landscape through a comprehensive analysis of disease symptoms, diagnostic methods, etiology, pathophysiology, epidemiology, prognosis and treatment.
Visualize the composition of the uveitis market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
Analyze the uveitis pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
Predict uveitis market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
Identify commercial opportunities in the uveitis deals landscape by analyzing trends in licensing and co-development deals.
Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Disease Introduction 9
2.2 Epidemiology 10
2.3 Symptoms 11
2.4 Etiology and Pathophysiology 11
2.4.1 Autoimmune uveitis 12
2.4.2 Non-autoimmune uveitis 12
2.5 Diagnosis 14
2.6 Prognosis 15
2.7 Treatment Options 16
2.7.1 Corticosteroids 17
2.7.2 Immunosuppressive Agents 18
2.7.3 Biologics 18
2.7.4 Adjuvant Therapy 19
3 Marketed Products 20
3.1 Overview 20
3.1.1 Humira (adalimumab) - AbbVie 21
3.1.2 Retisert (fluocinolone acetonide) - Bausch & Lomb 22
3.1.3 Ozurdex (dexamethasone) - Allergan 23
3.1.4 Neoral (Cyclosporine) - Novartis 25
3.1.5 Mycept (Mycophenolate mofetil) - Panacea Biotec 26
3.1.6 Medrol (Methylprednisolone) - Pfizer 27
3.1.7 Betamethasone - Merck & Co. 28
3.1.8 Pred Forte (Prednisolone) - Allergan 28
3.2 Comparative Efficacy and Safety of Marketed Products 29
4 Pipeline Analysis 32
4.1 Overview 32
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 33
4.3 Pipeline by Molecular Target 34
4.4 Promising Pipeline Candidates 36
4.4.1 DE-109/ Opsiria (Sirolimus) - Santen 36
4.4.2 CLS-TA (triamcinolone acetonide) - Clearside BioMedical 37
4.5 Heatmap for Pipeline Products 38
4.6 Product Competitiveness Framework 40
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1641312
5 Clinical Trial Analysis 42
5.1 Failure Rate 42
5.1.1 Overall Failure Rate 42
5.1.2 Failure Rate by Phase and Molecule Type 43
5.1.3 Failure Rate by Phase and Molecular Target 44
5.2 Clinical Trial Size 45
5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development 45
5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development 46
5.2.3 Patient Enrollment per Trial by Molecule Type and Stage of Development 47
5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development 48
5.3 Clinical Trial Duration 49
5.3.1 Trial Duration by Molecule Type and Stage of Development 49
5.3.2 Trial Duration by Molecular Target and Stage of Development 50
5.4 Summary of Clinical Trial Metrics 51
Continue...
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on @ https://marketsizeinfo.blogspot.in/
No comments:
Post a Comment